Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Avandia/Insulin Use Based On 220-Patient Study Showing No Cardio Risk

Executive Summary

GlaxoSmithKline's long-awaited approval of Avandia in combination with insulin is based on a 220-patient study showing no cardiovascular safety signal in type 2 diabetes patients

You may also be interested in...



GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies

GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials

GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies

GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials

Avandia/Metformin Combo To Launch By End Of 2002, GSK Says

GlaxoSmithKline's Avandia/metformin combination diabetes product will be launched by the end of 2002, GSK Chief Operating Officer Bob Ingram told securities analysts

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel